Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TARSthis companyTarsus Pharmaceuticals, Inc.	$68.81	-51.5×	9.96×	7.58×	-62.14×	-639.1%	93.2%	-15.7%	-14.7%	-19.3%	-16.6%	-0.7%	0.27×	1.68×	-7.94×	3.85×	0.0%	3	8.3	1	D+
ARQTArcutis Biotherapeutics, Inc.	$26.04	-223.38×	19.5×	9.82×	2,055.19×	-632.3%	90.2%	-3.3%	-4.3%	-8.5%	-4.0%	-0.2%	0.03×	-20.58×	-1.01×	3.17×	0.0%	7	7.53	2	C+
HROWHarrow Health, Inc.	$26.41	-350×	34.35×	6.61×	47×	-1507.5%	75.1%	14.2%	-1.9%	-9.8%	12.7%	2.4%	4.8×	4.25×	1.6×	2.2×	0.0%	4	1.85	1	C-
TTRXTurn Therapeutics Inc.	$9.64	-17.13×	11.55×	0×	-15.65×	-98.2%	0.0%	0.0%	0.0%	-68.2%	-94.4%	-5.0%	0.02×	1.59×	0×	0.87×	0.0%	1	7.69	1	D+
VRCAVerrica Pharmaceuticals Inc.	$3.39	-4.95×	3.58×	2.49×	-6.41×	-495.6%	90.3%	-33.6%	-50.3%	-72.3%	-38.0%	-19.9%	0.07×	3.05×	-1.54×	2.59×	0.0%	4	-13.81	1	D+
Peer median	—	-120.26×	15.53×	4.55×	20.3×	-564.0%	82.6%	-1.6%	-3.1%	-39.0%	-21.0%	-2.6%	0.05×	2.32×	-0.51×	2.39×	0.0%	4	4.69	1	—